Doctor with patient. Image credit: Canva
Mesothelioma is an aggressive cancer that grows in the linings of the body, including the membranes that line the heart, lungs and internal organs. Mesothelin (MSLN) is a protein that appears in high numbers in many tumors, including mesothelioma. Researchers are developing a new treatment that collects a person’s own immune cells, which are then genetically modified to target and kill tumor cells with high levels of MSLN.
A clinical trial led by Raffit Hassan, M.D., Chief and Senior Investigator in the Thoracic and GI Malignancies Branch, is researching this immunotherapy treatment for adults with solid tumors, including mesothelioma.
The trial will take place at the NIH Clinical Center in Bethesda, Maryland, and there is no cost for medical care received at the Clinical Center.
For more information, please contact the NCI Cancer Information Service at 1-888-624-1937 or nciinfo@mail.nih.gov
Clinicaltrials.gov identifier: NCT06885697
NCI Protocol ID: IRB002021
Official Title: Phase 1 Study With Dose Expansion of the Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care. Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland.
For more information on CCR clinical trials click here, and subscribe to have the latest CCR clinical trials sent directly to your inbox.
